A free webinar is being provided for the Australian clinical trials sector to discuss the impacts of COVID-19 (coronavirus).
Sector experts across the clinical trials eco-system, including industry, regulators, health departments, HRECS, and sites, will provide information, advice and a chance to discuss the impacts. The webinar is independently conducted by PRAXIS.
Australian biotech companies are at the forefront of the global response to COVID-19, which is continuing to rapidly spread across the world. This world-class biomedical research is part of a global vaccine development pipeline, and is testimony to the substantial contribution the Australian life sciences ecosystem delivers to the world.
Clinical trials are worth around $1 billion to the Australian economy annually, including around $650 million of foreign investment, with Australia attracting trials from around the world. They are a critical component in the development process of bringing new therapies, devices and diagnostics to patients.
The webinar will be held on 25 March, 12.00 – 1.30 pm AEDST.
Register now: https://praxisaustralia.com.au/enrol-now